{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:37:08Z","timestamp":1784029028092,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"crossref","award":["KFS-4851-08-2019"],"award-info":[{"award-number":["KFS-4851-08-2019"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"crossref","award":["KFS-5405-08-2021"],"award-info":[{"award-number":["KFS-5405-08-2021"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"crossref","award":["310030_192648"],"award-info":[{"award-number":["310030_192648"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"crossref","award":["310030_2127661\/1"],"award-info":[{"award-number":["310030_2127661\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stiftung zur Krebsbek\u00e4mpfung","award":["SKB503\/AHW\/de"],"award-info":[{"award-number":["SKB503\/AHW\/de"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-69347-x","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:02:25Z","timestamp":1722942145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment"],"prefix":"10.1038","volume":"14","author":[{"given":"Darya","family":"Karatkevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Losmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Zens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corsin","family":"Casty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Neppl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Berezowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Wang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph Alexander","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Michael","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"2\u20133","key":"69347_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","volume":"9","author":"H Yang","year":"2008","unstructured":"Yang, H., Testa, J. R. & Carbone, M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Opt. Oncol. 9(2\u20133), 147\u2013157 (2008).","journal-title":"Curr. Treat. Opt. Oncol."},{"issue":"2","key":"69347_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/OP.21.00608","volume":"18","author":"AA Kulkarni","year":"2022","unstructured":"Kulkarni, A. A. & Kratzke, R. A. A turning point for mesothelioma therapy. JCO Oncol. Pract. 18(2), 125\u2013126 (2022).","journal-title":"JCO Oncol. Pract."},{"issue":"5","key":"69347_CR3","doi-asserted-by":"publisher","first-page":"574","DOI":"10.21037\/tlcr.2018.04.10","volume":"7","author":"CJ de Gooijer","year":"2018","unstructured":"de Gooijer, C. J., Baas, P. & Burgers, J. A. Current chemotherapy strategies in malignant pleural mesothelioma. Transl. Lung Cancer Res. 7(5), 574\u2013583 (2018).","journal-title":"Transl. Lung Cancer Res."},{"issue":"19","key":"69347_CR4","doi-asserted-by":"publisher","first-page":"11949","DOI":"10.3390\/ijms231911949","volume":"23","author":"D Karatkevich","year":"2022","unstructured":"Karatkevich, D. et al. Schedule-dependent treatment increases chemotherapy efficacy in malignant pleural mesothelioma. Int. J. Mol. Sci. 23(19), 11949 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"69347_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12885-016-2117-4","volume":"16","author":"CC Tieche","year":"2016","unstructured":"Tieche, C. C. et al. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT. BMC Cancer 16(1), 125 (2016).","journal-title":"BMC Cancer"},{"issue":"1","key":"69347_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12935-016-0346-x","volume":"16","author":"P Dorn","year":"2016","unstructured":"Dorn, P. et al. Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells. Cancer Cell Int. 16(1), 66 (2016).","journal-title":"Cancer Cell Int."},{"issue":"1","key":"69347_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100(1), 57\u201370 (2000).","journal-title":"Cell"},{"key":"69347_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1037-1","author":"Y Gao","year":"2019","unstructured":"Gao, Y. et al. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. Cancer Cell Int. https:\/\/doi.org\/10.1186\/s12935-019-1037-1 (2019).","journal-title":"Cancer Cell Int."},{"key":"69347_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1101\/sqb.2012.76.010900","volume":"76","author":"MG Vander Heiden","year":"2011","unstructured":"Vander Heiden, M. G. et al. Metabolic pathway alterations that support cell proliferation. Cold Spring Harb. Symp. Quant. Biol. 76, 325\u2013334 (2011).","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"69347_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.23.465566","volume-title":"Cytidine Deaminase Protects Pancreatic Cancer Cells from Replicative Stress and Drives Resistance to DNA-Targeting Drugs","author":"A Lumeau","year":"2021","unstructured":"Lumeau, A. et al. Cytidine Deaminase Protects Pancreatic Cancer Cells from Replicative Stress and Drives Resistance to DNA-Targeting Drugs (Cold Spring Harbor Laboratory, 2021)."},{"key":"69347_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2016.08.001","volume":"50","author":"SW Lam","year":"2016","unstructured":"Lam, S. W., Guchelaar, H. J. & Boven, E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat. Rev. 50, 9\u201322 (2016).","journal-title":"Cancer Treat. Rev."},{"issue":"47","key":"69347_CR12","doi-asserted-by":"publisher","first-page":"82705","DOI":"10.18632\/oncotarget.19751","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen, X., Yang, Y. & Katz, S. Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging. Oncotarget 8(47), 82705\u201382713 (2017).","journal-title":"Oncotarget"},{"issue":"4","key":"69347_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/cells11040739","volume":"11","author":"M Walter","year":"2022","unstructured":"Walter, M. & Herr, P. Re-discovery of pyrimidine salvage as target in cancer therapy. Cells 11(4), 739 (2022).","journal-title":"Cells"},{"issue":"2","key":"69347_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neo.2018.09.008","volume":"21","author":"CC Tieche","year":"2019","unstructured":"Tieche, C. C. et al. Tumor initiation capacity and therapy resistance are differential features of EMT-related subpopulations in the NSCLC cell line A549. Neoplasia 21(2), 185\u2013196 (2019).","journal-title":"Neoplasia"},{"issue":"1","key":"69347_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-021-01938-2","volume":"40","author":"Y Gao","year":"2021","unstructured":"Gao, Y. et al. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5\u2019-deoxy-5-fluorocytidine (5\u2019-DFCR). J. Exp. Clin. Cancer Res. 40(1), 138 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"69347_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vascn.2014.11.003","volume":"71","author":"M Xu","year":"2015","unstructured":"Xu, M., McCanna, D. J. & Sivak, J. G. Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells. J. Pharmacol. Toxicol. Methods 71, 1\u20137 (2015).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"69347_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","volume":"9","author":"N Fedchenko","year":"2014","unstructured":"Fedchenko, N. & Reifenrath, J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue\u2014A review. Diagn. Pathol. 9, 221\u2013221 (2014).","journal-title":"Diagn. Pathol."},{"issue":"1","key":"69347_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1479-5876-11-104","volume":"11","author":"I Zlobec","year":"2013","unstructured":"Zlobec, I. et al. Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J. Transl. Med. 11(1), 104 (2013).","journal-title":"J. Transl. Med."},{"key":"69347_CR19","doi-asserted-by":"publisher","DOI":"10.3791\/51893","author":"AU Zlobec","year":"2014","unstructured":"Zlobec, A. U. et al. A next-generation tissue microarray (ngTMA) protocol for biomarker studies. JoVE https:\/\/doi.org\/10.3791\/51893 (2014).","journal-title":"JoVE"},{"issue":"2","key":"69347_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","volume":"28","author":"A Frances","year":"2020","unstructured":"Frances, A. & Cordelier, P. The emerging role of cytidine deaminase in human diseases: A new opportunity for therapy?. Mol. Ther. 28(2), 357\u2013366 (2020).","journal-title":"Mol. Ther."},{"issue":"19","key":"69347_CR21","doi-asserted-by":"publisher","first-page":"e2102050118","DOI":"10.1073\/pnas.2102050118","volume":"118","author":"AP Deshmukh","year":"2021","unstructured":"Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl. Acad. Sci. 118(19), e2102050118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"69347_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s12885-018-4720-z","volume":"18","author":"MC Kim","year":"2018","unstructured":"Kim, M. C. et al. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma. BMC Cancer 18(1), 819 (2018).","journal-title":"BMC Cancer"},{"issue":"1","key":"69347_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2015.07.015","volume":"90","author":"RJ Francis","year":"2015","unstructured":"Francis, R. J. et al. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer 90(1), 55\u201360 (2015).","journal-title":"Lung Cancer"},{"issue":"8","key":"69347_CR24","doi-asserted-by":"publisher","first-page":"e105994","DOI":"10.1371\/journal.pone.0105994","volume":"9","author":"M Zhang","year":"2014","unstructured":"Zhang, M. et al. Induction of peroxiredoxin 1 by hypoxia regulates heme oxygenase-1 via NF-\u03baB in oral cancer. PLoS ONE 9(8), e105994 (2014).","journal-title":"PLoS ONE"},{"issue":"8","key":"69347_CR25","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-16-0626","volume":"23","author":"H Mameri","year":"2017","unstructured":"Mameri, H. et al. Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer. Clin. Cancer Res. 23(8), 2116\u20132126 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"69347_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","volume":"54","author":"H Easwaran","year":"2014","unstructured":"Easwaran, H., Tsai, H. C. & Baylin, S. B. Cancer epigenetics: Tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54(5), 716\u2013727 (2014).","journal-title":"Mol. Cell"},{"issue":"1","key":"69347_CR27","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/s41467-019-13441-6","volume":"10","author":"LG Karacosta","year":"2019","unstructured":"Karacosta, L. G. et al. Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nat. Commun. 10(1), 5587 (2019).","journal-title":"Nat. Commun."},{"issue":"11","key":"69347_CR28","doi-asserted-by":"publisher","first-page":"100845","DOI":"10.1016\/j.tranon.2020.100845","volume":"13","author":"K Saxena","year":"2020","unstructured":"Saxena, K., Jolly, M. K. & Balamurugan, K. Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis. Transl. Oncol. 13(11), 100845 (2020).","journal-title":"Transl. Oncol."},{"issue":"24","key":"69347_CR29","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.3390\/ijms20246140","volume":"20","author":"AA Tirpe","year":"2019","unstructured":"Tirpe, A. A. et al. Hypoxia: Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int. J. Mol. Sci. 20(24), 6140 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"1035","key":"69347_CR30","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown, S. R. Defining normoxia, physoxia and hypoxia in tumours\u2014Implications for treatment response. Br. J. Radiol. 87(1035), 20130676 (2014).","journal-title":"Br. J. Radiol."},{"key":"69347_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00343","author":"L Cantini","year":"2020","unstructured":"Cantini, L. et al. Emerging treatments for malignant pleural mesothelioma: Where are we heading?. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.00343 (2020).","journal-title":"Front. Oncol."},{"issue":"2","key":"69347_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.lungcan.2003.10.011","volume":"44","author":"GA Otterson","year":"2004","unstructured":"Otterson, G. A. et al. Capecitabine in malignant mesothelioma: A phase II trial by the cancer and leukemia group B (39807). Lung Cancer 44(2), 251\u2013259 (2004).","journal-title":"Lung Cancer"},{"issue":"5","key":"69347_CR33","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/jcm12051757","volume":"12","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud, M. et al. The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma. J. Clin. Med. 12(5), 1757 (2023).","journal-title":"J. Clin. Med."},{"issue":"8","key":"69347_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s12276-022-00836-7","volume":"54","author":"H Heo","year":"2022","unstructured":"Heo, H. et al. DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor\u2013resistant lung cancer therapy. Exp. Mol. Med. 54(8), 1236\u20131249 (2022).","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"69347_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12094-009-0403-1","volume":"11","author":"C Mendiola","year":"2009","unstructured":"Mendiola, C. & Vaz, M. A. Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. Clin. Transl. Oncol. 11(8), 554\u2013557 (2009).","journal-title":"Clin. Transl. Oncol."},{"issue":"6","key":"69347_CR36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/cancers15061821","volume":"15","author":"Y Cura","year":"2023","unstructured":"Cura, Y. et al. Influence of single-nucleotide polymorphisms on clinical outcomes of capecitabine-based chemotherapy in colorectal cancer patients: A systematic review. Cancers (Basel) 15(6), 1821 (2023).","journal-title":"Cancers (Basel)"},{"issue":"26","key":"69347_CR37","doi-asserted-by":"publisher","first-page":"E5226","DOI":"10.1073\/pnas.1705066114","volume":"114","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proc. Natl. Acad. Sci. 114(26), E5226\u2013E5235 (2017).","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69347-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69347-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T11:11:10Z","timestamp":1722942670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69347-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["69347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-69347-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18206"}}